Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Lipid-lowering on FFRct in Stable Chest Pain
NCT05368545Completed
- Sponsor
- Aarhus University Hospital
- Start
- May 2020
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of rosuvastatin and ezetimibe in coronary artery disease (CAD) (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Changes in FFRct values at 18 months. Started May 2020; status: completed.
02
Drugs
rosuvastatinezetimibe
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05368545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05368545.